Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.

doi:10.1038/modpathol.2013.81

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Nov 2013

Diaz Zuanel, Aguilar-Mahecha Adriana, Paquet Eric R, Basik Mark, Orain Michèle, Camlioglu Errol, Constantin André, Benlimame Naciba, Bachvarov Dimcho, Jannot Guillaume, Simard Martin J, Chabot Benoit, Gologan Adrian, Klinck Roscoe, Gagnon-Kugler Thérèse, Lespérance Bernard, Samson Benoit, Kavan Petr, Alcindor Thierry, Dalfen Richard, Lan Cathy, Chabot Catherine, Buchanan Marguerite, Przybytkowski Ewa, Qureshi Samia, Rousseau Caroline, Spatz Alan, Têtu Bernard, Batist Gerald

Abstract excerpt

Great advances in analytical technology coupled with accelerated new drug development and growing understanding of biological challenges, such as tumor heterogeneity, have required a change in the focus for biobanking. Most current banks contain samples of primary tumors, but linking molecular signatures to therapeutic questions requires serial biopsies in the setting of metastatic disease, next-generation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Canada

Share to Comparative Genomic Hybridization

Share to Patient Selection

Share to Precision Medicine

Share to Specimen Handling

Share to Tissue Banks

Share to Workflow

Source

Open in PubMed

Identifiers

PMID: 23743930
DOI: 10.1038/modpathol.2013.81

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.PMID 23743930Read ↗

Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) SamplesSemantic proximity Read ↗

Rapid and Large-Scale Transition of New Tumor Biomarkers to Clinical Biopsy Material by Innovative Tissue Microarray SystemsSemantic proximity Read ↗

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.Semantic proximity Read ↗

A Bioinformatic Pipeline to Identify Biomarkers for Metastasis Formation from RNA Sequencing Data.Semantic proximity Read ↗

Application of molecular profiling in clinical trials for advanced metastatic cancers.Semantic proximity Read ↗

Proteomic strategies and challenges in tumor metastasis researchSemantic proximity Read ↗

Optimizing nucleic acid extraction and transcriptome evaluation from low-input, fixed clinical samplesSemantic proximity Read ↗

Microscaled Proteogenomic Methods for Precision OncologySemantic proximity Read ↗

Mapping Spatial Genetic Landscapes in Tissue Sections through Microscale Integration of Sampling Methodology into Genomic Workflows.Semantic proximity Read ↗

Tissue Microarray: A rapidly evolving diagnostic and research toolSemantic proximity Read ↗

Standardization and Harmonization of Distributed Multi-National Proteotype Analysis supporting Precision Medicine StudiesSemantic proximity Read ↗

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.